Tech Center 1600 • Art Units: 1622 1625
This examiner grants 81% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18555640 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Non-Final OA | Merck Sharp & Dohme LLC |
| 18569432 | METHOD OF TREATING AN AUTOIMMUNE HEMATOLOGICAL DISORDER | Non-Final OA | Novartis AG |
| 18569571 | PHARMACEUTICAL COMPOSITION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID | Non-Final OA | LG CHEM, LTD. |
| 18569568 | PHARMACEUTICAL COMPOSITION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID | Non-Final OA | LG CHEM, LTD. |
| 18747540 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Non-Final OA | Mindset Pharma Inc. |
| 18452008 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | Non-Final OA | ASTRAZENECA AB |
| 18269168 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18272367 | Synthesis of furandicarboxylic acid from aldaric acid | Non-Final OA | Teknologian tutkimuskeskus VTT Oy |
| 18551614 | PROCESS FOR PREPARING (2Z)-2-(PHENYLIMINO)-1,3-THIAZOLIDINE-4-ONE-SULFOXIDE DERIVATIVES IN AN ENANTIOMERICALLY ENRICHED FORM | Non-Final OA | Bayer Aktiengesellschaft |
| 18247795 | METHOD FOR PRODUCING CARBONYLAMINOFURANS | Non-Final OA | Bayer Aktiengesellschaft |
| 18563284 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | Non-Final OA | Université de Montpellier |
| 18254320 | PRODUCT OF INTERNAL DEHYDRATION OF HIGH-PURITY SORBITOL | Non-Final OA | ROQUETTE FRERES |
| 18571860 | SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF | Non-Final OA | Jazz Pharmaceuticals Ireland Limited |
| 18288296 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FIBROSIS | Non-Final OA | Daewoong Pharmaceutical Co., Ltd. |
| 18566134 | EYE DROP COMPOSITION FOR PREVENTION OR TREATMENT OF OPHTHALMIC DISEASES AND PREPARATION METHOD THEREFOR | Non-Final OA | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. |
| 18554474 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | Non-Final OA | UNIVERSITÄT BASEL |
| 18279103 | Methods of Reducing Risk of Prostate Cancer Progression | Non-Final OA | Astellas Pharma Inc. |
| 18288338 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CYSTIC FIBROSIS | Non-Final OA | Insmed Incorporated |
| 18555567 | EASY CHEW FORMULATIONS | Non-Final OA | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| 18283158 | VACCINE ADJUVANT | Non-Final OA | Celleron Therapeutics Limited |
| 18465928 | DELTA-8 TETRAHYDROCANNABINOL (THC) OIL, METHOD OF MAKING DELTA-8 THC OIL, AND COMPOSITIONS THEREOF | Non-Final OA | CCT SCIENCES, LLC |
| 18226226 | Application of Aristolochic Acid IVa in Preparation of Antihistamine or Drug for Treating Pneumonia | Final Rejection | Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences |
| 18267905 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | Non-Final OA | The Schepens Eye Research Institute, Inc. |
| 18248846 | OXIDATIVE PRETREATMENT OF CARBOHYDRATE DEHYDRATION PRODUCTS COMPRISING HUMINS | Non-Final OA | Archer Daniels Midland Company |
| 18058441 | SYNTHESIS OF HALICHONDRINS | Non-Final OA | Eisai R&D Management Co., LTD. |
| 18025979 | NEW MEDICAL USE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS | Final Rejection | Charité-Universitätsmedizin Berlin |
| 17999743 | MACROCYCLIC JAK INHIBITOR AND USE THEREOF | Non-Final OA | Biopolar Hongye (Nantong) Pharmaceutical Co., Ltd. |
| 17923782 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS | Final Rejection | GRETALS AUSTRALIA PTY LTD |
| 17974443 | N-N-DIMETHYLTRYPTAMINE (DMT) AND DMT ANALOG COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Final Rejection | ATAI Life Sciences AG |
| 17969043 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Non-Final OA | Morphic Therapeutic, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy